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Abstract
The molecular causes by which the epidermal growth factor receptor tyrosine kinase induces malignant transformation are
largely unknown. To better understand EGFs’ transforming capacity whole genome scans were applied to a transgenic
mouse model of liver cancer and subjected to advanced methods of computational analysis to construct de novo gene
regulatory networks based on a combination of sequence analysis and entrained graph-topological algorithms. Here we
identified transcription factors, processes, key nodes and molecules to connect as yet unknown interacting partners at the
level of protein-DNA interaction. Many of those could be confirmed by electromobility band shift assay at recognition sites
of gene specific promoters and by western blotting of nuclear proteins. A novel cellular regulatory circuitry could therefore
be proposed that connects cell cycle regulated genes with components of the EGF signaling pathway. Promoter analysis of
differentially expressed genes suggested the majority of regulated transcription factors to display specificity to either the
pre-tumor or the tumor state. Subsequent search for signal transduction key nodes upstream of the identified transcription
factors and their targets suggested the insulin-like growth factor pathway to render the tumor cells independent of EGF
receptor activity. Notably, expression of IGF2 in addition to many components of this pathway was highly upregulated in
tumors. Together, we propose a switch in autocrine signaling to foster tumor growth that was initially triggered by EGF and
demonstrate the knowledge gain form promoter analysis combined with upstream key node identification.
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Introduction
Epidermal growth factor is an important mitogen for hepatocytes
for its ability to modulate proto-oncogene as well as liver specific
gene expression. To better understand EGF’s role in malignant
transformation a transgenic mouse model was developed where
EGF was targeted to the liver. Notably, transgenic mice developed
liver cancer around 7–8 months and a tumour stage-dependent
network of EGF-regulated genes was identified, as previously
reported [1]. Encouraged by these findings genes linked to
tumorigenes and progression of disease could be proposed. Here,
we wished to analyze gene expression profiles of pre-tumorous and
highly differentiated hepatocellular carcinomas with a novel
computational method that enabled identification of regulators of
the EGF signalling cascade associated with malignant transforma-
tion. A new method was developed based on promoter sequence
analysis of differentially expressed genes. Specifically, transcription
of a gene is determined to a major part by the activity of
transcription factors, which in turn recognize specific short DNA
segments, i.e. transcription factor binding sites (TFBSs) which are
often situated in the promoter region upstream of the transcription
start site (TSS). Gene expression profiles can thus be used to identify
TFs that potentially influence the expression of genes under certain
cellular conditions by use of variousgenetic algorithms and matrices
that recognise TFBSs. The complexity of the gene expression data
can then be reduced by identification of common TFs of co-
regulated genes. The here described and newly developed method
focuses on the identificationof transcriptionfactor bindingsiteswith
co-occupancy in the promoters of differentially expressed genes in a
statistically significant manner. This enabled hypotheses generation
and an identification of transcription factors acting on such a
promoter set with the ultimate goal to identify ‘‘molecular triggers’’
in gene regulatory networks forcing hepatocytes into malignant
transformation. Based on such analysis transcription factors were
identified as candidate effectors of malignant transformation which
may function in the switch from EGF over expression to the
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tional predictions Western blotting experiments of nuclear proteins
and EMSA band shift assays were carried out to determine the
DNA binding activity of several transcription factors. Reconstruc-
tion of signalling cascades upstream of these TFs allowed us to
suggest the downstream targets of EGF signalling in these two types
of cellular states, i.e. transgenicity and liver cancer. As a result, we
propose regulatory networks that help to better understand EGF-
induced malignancies. In an effort to search for key molecules in the
signalling network upstream of the identified transcription factors
the insulin-like growth factor pathway was identified that indeed
may represent a molecular switch from the EGF receptor tyrosine
kinase route to the tumour state thereby rendering malignantly
transformed cells independent of EGF receptor activity. Further
evidence for this hypothesis was obtained when the gene expression
of IGF2 and its down stream partners was investigated and
determined to be highly significantly induced in tumour cells as
were many components of this pathway.
Overall this study aims for a better understanding of the EGF
transforming capacity and combines different lines of evidence for
a possible mechanism of disease.
Results
Differential expression in transgenic (pre-tumor) and
tumor tissue: sub classification of known liver cancer
biomarkers by gene expression profiles
ExPlain 2.3 mapped Affymetrix probe sets to 10,262 mouse
genes. Differential expression analysis with Ebarrays detected 303
and 355 up regulated genes as well as 95 and 141 down regulated
genes in transgenic and tumor cells, respectively. Table 1
summarizes information about obtained gene lists and Figure 1
depicts the distribution of known transcription factor binding site
locations according to the TRANSFAC database release 12.1 (see
Material and Methods, calculation of P-values for MATCH
scores, for further details). Table S1 provides all MGI gene
symbols, TRANSPATH molecule names, if available, and highest
or lowest fold changes measured for probe sets of up regulated or
down regulated genes, respectively. A minor manual modification
was introduced to gene set 5 (Table 1), where a probe set mapped
to four closely related paralogs Bcl2a1a–d. We used the MAFFT
alignment software [2] and Jalview [3] to inspect the multiple
alignments of Bcl2a1 promoters (Figure S1). Since promoter
sequences of these genes are very similar, a bias in promoter
analyses performed in this work could be expected and we
therefore removed three Bcl2a genes (b–d) from gene set 5.
Transgenic and tumor states shared 144 up regulated genes and
25 down regulated genes (sets 3 and 8, Table 1). In subsequent
analyses we also considered a potentially larger overlap, when a
probe set was statistically significant in one contrast and achieved a
high fold change in the other (sets 2, 4, 7, and 9). Thus, for 77 of
the 303 up regulated genes in transgenic cells (set 2), a probe set
detected by statistical analysis also had a fold change .2 in tumor
cells, and these 77 genes were added to the 355 genes up regulated
in tumor to obtain an extended set of up regulated genes in tumor
cells. Correspondingly, 103 of the 355 genes up regulated in tumor
were appended to the transgenic set to derive an extended set of
up regulated genes in transgenic cells (set 4). Likewise, gene sets of
the down regulation response were enlarged at a fold change
below 0.5. Remaining subsets (sets 1, 5, 6, and 10) were considered
specifically regulated in the respective progression state.
According to the disease module of the BIOBASE Knowledge
Library (BKL) [4], EGF-induced carcinogenesis caused differential
expression of 39 known biomarker genes associated with liver
carcinoma/neoplasms (Table S1). As shown in Figure 2, these
biomarkers featured different patterns of expression suggesting a
further sub classification with regard to their response in pre-
tumor and tumor state. Three genes, namely Myc, Glul, Oat, were
transiently up- or down regulated during disease onset and may
thus serve as early markers for liver cancer, which discriminate
against the tumor state (Figure 2A). Statistical analysis also
suggested Dnmt3a, Itga6, and Shc1, however high fold changes
were measured for these genes in tumor cells as discussed above.
Expression of 14 biomarker genes changed detectably in both
progression states (Figure 2B) indicating an additional set of
putative early liver cancer markers. Finally, Ccnd1, Gpc3, Mvk,
Pparg, Rbl2, and Robo1 exhibited a tumor-specific response
(Figure 2C), where adverse expression changes were observed for
Pparg, which appeared down regulated in transgenic cells (fold
change ,0.4) and significantly up regulated in tumors. Taken
together, these results suggest a refined interpretation of known
biomarkers for liver cancer/neoplasms. Among respective genes
we could identify several informative signatures that indicate
specific pre-tumor and tumor markers and show that expression
changes of some known biomarkers may in fact serve as early
indicators of disease onset.
Regulation of cell cycle and lipid metabolism changes
progressively in EGF-induced hepatocarcinogenesis
With defined sets of differentially expressed (DE) genes at hand,
we set out to identify functional changes that accompany EGF-
induced hepatocarcinogenesis. For this purpose, we calculated
enrichment P-values for all GO Biological Process categories
associated with at least one gene in transgenic or tumour gene sets
and applied them as a measure of relative importance of a
particular biological function for a given gene set. To limit the
effect of false negative findings during differential expression
analysis, enrichment P-values were calculated for extended gene
sets composed of sets 1–4 (up regulated in transgenic cells), 2–5 (up
regulated in tumor cells), 6–9 (down regulated in transgenic cells),
and 7–10 (down regulated in tumour cells) (Table 1). Results of the
P-value comparison are shown in Figure 3. In the following we
focus on the 15 GO groups with largest differences between log-P-
values as obtained in analyses of either upregulated or downreg-
ulated gene sets. Plots of transgenic versus tumour P-values
(Figure 3, A and C) illustrate that the procedure ordered categories
according to their distance to the diagonal (red line). Points on the
diagonal indicate no difference between P-values. In the selected
top 15 biological processes, P-values varied by about 2–6 orders of
magnitude between transgenic and tumour states. According to
this analysis, upregulation of genes during tumorigenes most
strongly altered cell cycle functions (Figure 3B). Note that legends
of Figures 3B and 3D preserve the ordering by log-P-value
difference. All of the top five GO categories, ‘‘cell division’’, ‘‘cell
cycle’’, ‘‘M phase’’, ‘‘mitosis’’, and ‘‘M phase of mitotic cell cycle’’
allude to changes in cell cycle and were more significantly
enriched in the tumor gene set, whereas upregulation in transgenic
cells was more strongly directed at mechanisms of cell motility as
well as cellular component organization and biogenesis. Besides
alterations of cell cycle, functional comparison points out changes
in regulation of genes taking part in developmental processes, cell
growth, and anatomical structure development (Figure 3B), which
imply potential dedifferentiation events. Analysis of downregula-
tion responses reveals that regulation of lipid metabolism was
strongly modified during tumorigenesis. The next two highest
ranked functions pertain to protein deubiquitination and bile acid
synthesis (Figure 3D). Table S2 provides additional details about
genes matching some selected biological process groups and their
Oncogenic Signalling of EGFR in Liver Cancer
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ranked by comparison of upregulated gene sets were significantly
affected in both transgenic and tumor cells, which shows that these
functions undergo progressive alterations. In particular, genes
associated with anatomical structure development were strongly
enriched in transgenic and tumor sets (yellow dot and line,
Figure 3, A and B). Notably, differences manifested not only in
upregulation of additional genes in the tumor cell; e.g. the cell
cycle group of transgenic cells comprises Foxc1, Gadd45a, Hic1,
Hus1, Myc, and Uhmk1, which were not detected in tumor
(despite extension of the gene list). The most dramatic changes
were observed in regulation of lipid metabolic genes. Transgenic
and tumor gene sets involved in this function differed by 21 genes
and enrichment P-values increased by about six orders of
magnitude. Furthermore, protein deubiquitination and bile acid
metabolism exhibit a switch-like regulation, where differential
expression was first detected in the tumor.
Cell-cycle dysregulation was previously identified as one causal
mechanism of nongenotoxic carcinogenicity [5]. It is also known
that liver cancer entails lipid metabolic derangements including
cholesterol metabolism [6]. The results presented here show that
disease onset was accompanied by progressive changes in
respective functions. The ubiquitin-proteasome pathway is a
relatively new target for cancer therapy [7]. According to our
gene expression data, hepatocarcinogenesis caused downregula-
tion of three deubiquitination genes, Dub1, Dub2, and Dub2a,
specifically in the tumor state (Table S1). Recently, a deubiqui-
tinating enzyme, BAP1, with a role in cell cycle regulation was
Figure 1. Distribution of known transcription factor binding site locations (blue) according to the TRANSFAC database release 12.1.
The red line indicates the peak of the distribution at –115bp relative to the TSS.
doi:10.1371/journal.pone.0017738.g001
Table 1. Sets of differentially expressed genes in transgenic and tumor cells defined by statistical analysis and fold changes.
Gene set Progression state Fold change in other condition #genes
Upregulation
1 Transgenic Fold change #2 in tumor cells 82
2 Fold change .2 in tumor cells 77
3 Transgenic & Tumor 144
4 Tumor Fold change .2 in transgenic cells 103
5 Fold change #2 in transgenic cells 108
Downregulation
6 Transgenic Fold change $0.5 in tumor cells 47
7 Fold change ,0.5 in tumor cells 23
8 Transgenic & Tumor 25
9 Tumor Fold change ,0.5 in transgenic cells 24
10 Fold change $0.5 in transgenic cells 92
doi:10.1371/journal.pone.0017738.t001
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finding the corresponding GO category among the top 15 altered
functions despite a moderate enrichment P-value in the tumor
gene set (P,0.0001). Downregulation of deubiquitination genes
complies with previous findings, as Ventii and coauthors also
observed deficiency in deubiquitinating activity in cancer-associ-
ated mutants. In summary, progressive changes in regulation of
cell cycle, developmental and lipid metabolic functions chaper-
oned EGF-induced hepatocarcinogenesis, whereas potential
switch-like regulation was observed for small groups of genes
defined by protein deubiquitination and bile acid biosynthesis, a
component of hepatic cholesterol metabolism. These biological
functions may harbor novel biomarkers for disease onset and
tumorigenesis.
Clusters of upregulated signal transduction molecules in
transgenic and tumor cells integrate growth factor, cell
cycle, chemokine and cytokine signals
Networks of interacting proteins exert a large part of cellular
functions. Analysis of differentially expressed molecules in the
context of known signalling pathways enables identification of
molecular networks targeted by observed expression changes. We
applied network cluster analysis to propose functional context for
signaling components encoded by differentially expressed genes of
transgenicandtumorcellsalongwith supportingnetworktopologies
constructed from experimentally proven signaling reactions.
Networks were constructed for extended upregulation and down-
regulation gene sets described above. As a result, we obtained one
cluster each for upregulated genes of transgenic cells and for
upregulated genes of tumor cells. A small network of downregulated
genes was found in tumor cells, in which EGF and beta-c interact
with Shc and a complex comprising EGF, ErbB1, Shc-1, Grb2, and
Sos (not shown). The two networks of upregulated genes were
constituted by 85 and 88 components including 39 and 41
molecules upregulated in transgenic or tumor cells, respectively.
Diagrams of transgenic and tumor network clusters are shown in
Figures 4 and 5. Further information about differentially expressed
molecules and encoding genes is given in Table S3.
Both networks feature a mix of functional categories such as
growth factor signaling, e.g. through ErbB receptors, InsR, or
FGFR-1, cell cycle-regulatory cascades, e.g. involving cyclin B1,
Cdk1, Aurora-A, or p53, as well as cytokine and chemokine
signaling through IL-1RI and CXCR4. The combined list of
upregulated components consists of 48 proteins of which 7 are
specific to the transgenic network and 9 are only part of the tumor
network (Table S3). For 19 of the 32 shared molecules a
quantitative change in expression during tumorigenesis may be
hypothesized as indicated by node coloring on network diagrams
(green and light red nodes, Figures 4 and 5). Notably, this applies
to a compact module of cell cycle regulators, namely survivin,
cyclin B1, Cdk1, Plk1, and Bub1, whose expression increased
about 2-fold in tumor versus transgenic cells according to
measured fold changes. Moreover, network analysis suggests
another, tumor-specific module of cell cycle regulators formed
by p107, p130, p15INK4b, and Wee1 (Figure 5). These results
further support the hypothesis that EGF-induced carcinogenesis is
driven in part by progressive alterations of cell cycle regulation,
which, as the networks show, may also manifest through
quantitative changes of expression.
The presented network clusters reveal potential effects on the
activity of upregulated TFs like c-Fos, c-Jun, c-Myc, PPAR-
gamma1, Smad3, Egr-1, and c-Ets-2. C-Myc and PPAR-gamma1
were restricted to the transgenic and the tumor network,
respectively. Each factor integrates signals from several upstream
molecules with altered expression. Interestingly, well-known
cancer-associated TFs like c-Fos, c-Jun, Smad3, and c-Ets-2
exhibited rather constant levels of upregulation throughout
tumorigenesis. Furthermore, a relatively high number of both
activating and inhibitory reactions target p53, which was void of
detectable differential expression in either progression state.
A cascade involving VCAM-1, alpha4-integrin, and IAP was
found specifically in the transgenic network (Figure 4). Alpha4-
integrin shows progression state-specific regulation with upregula-
tion in transgenic cells and downregulation in tumor cells (Table
S3). Integrins are linked to tissue invasion by hepatocarcinoma
cells [9] and play a role in apoptosis [10]. BMP7, a tumor
network-specific molecule, can act as transcription factor and may
as such contribute to upregulation of c-Myb [11] as well as of c-
Fos, the latter possibly by other means [12]. BMP7 was previously
reported to participate in regulation of apoptosis in vascular
smooth muscle cells [13]. Given their association with apoptosis
and their progression state-specific expression profiles, alpha4-
Figure 2. Expression responses of known liver carcinoma/neoplasia biomarkers in EGF-induced carcinogenicity. The plots show log-
Fold changes of known biomarkers which were differentially expressed in transgenic cells (A), both states (B), or tumors (C). Fold changes of some
genes indicated differential expression in both states, although statistical analysis assigned them to one state only (dashed lines). Several known
biomarkers exhibited progression state-specific responses, which may subserve derivation of pre-tumor and tumor signatures (bold lines).
doi:10.1371/journal.pone.0017738.g002
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mechanisms of carcinogenesis.
The network clusters reveal regulatory circuitries that might be
explored for novel therapeutic interventions. Indeed, PPAR-
gamma antagonists are being investigated as treatment of various
malignancies including liver cancers. Regulatory cascades target-
ing PPAR-gamma through upstream kinases and phosphatases,
such as M3/6, JNK1, MEKK2, MKP3, MEK2, or ERK2, of
which M3/6, MEKK2, and MFP-3 were induced during
carcinogenesis, suggest additional possibilities for drug develop-
ment. Furthermore, the ligand of insulin and insulin-like receptors,
IGF-2, was strongly upregulated in tumor cells, whereas there
were moderate changes in transgenic cells (not detected by
differential expression analysis). The potential role of this ligand in
autocrine regulation of cancer cell growth was previously discussed
in the literature [14] and further analyzed in our study (see below).
Promoter analysis and identification of regulatory
sequences
Transcription factors are important contributors to coordinated
gene expression changes like those observed in the study data. It is
a standard approach to test for overrepresentation of TF binding
Figure 3. Comparison of Gene Ontology Biological Process enrichment in transgenic and tumor gene sets. (A and B – analysis of
upregulated genes, C and D – analysis of downregulated genes). A and C) Each dot represents a GO category in the space of two P-values. B and D)
Top 15 GO terms with greatest log-P-value difference between transgenic and tumor. Dots corresponding to categories listed in B and D are
highlighted in A and C, respectively.
doi:10.1371/journal.pone.0017738.g003
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promoters. We quantified binding site enrichment by the 0.01-
quantile of the ratio of two Beta distributions modeling the odds
ratio of predicted binding sites and promoters and foreground and
background gene sets. The 0.01-quantile value, in the following
denoted q-value, estimates the value of the odds ratio, so that the
true ratio is higher with 99% probability (see Methods). For each
of the 578 TRANSFAC PWMs, the algorithm started with a low
PWM score threshold (P-value 0.05) and iteratively adjusted the
cut-off (by incrementing) to maximize the q-value.
Binding sites were predicted by MATCH in promoter regions
covering 21000 to +100 relative to the TSS. We constructed
separate background sets for transgenic and tumor cells by
randomly sampling 1000 genes with fold changes between 0.9 and
1.1 in the respective progression state. The following foreground
sets were analyzed: upregulation (Table 1: sets 1–3 and 3–5),
specific upregulation (Table 1: sets 1 and 5), downregulation
(Table 1: sets 6–8 and 8–10), and specific downregulation (Table 1:
sets 6 and 10). In addition, binding site enrichment was tested in
promoters of upregulated genes associated with cell cycle and of
downregulated genes associated with lipid metabolism.
In Figure 6, q-values of TRANSFAC motifs optimized for
transgenic foreground sets are plotted against q-values of corre-
sponding tumor foreground sets. Furthermore, we extracted the top
PWMs ordered by q-values in Table S4. Identifiers of TRANSFAC
matrices whose dots are highlighted in Figure 6 are bold-typed in
Table S4. Extraction of matrices followed the rule to show the top
15 PWMs, or all with at least 2-fold enrichment in either transgenic
or tumor set, or all PWMs highlighted in Figure 6, whichever
resulted in the largest number of motifs. We also extracted
transcription factor genes (Table S5) according to identified PWMs
(underlined in Table S4) and performed upstream network analysis
with transcription factor sets (see below).
As a result, promoter analysis revealed TF motifs specifically, or
more articulately overrepresented in transgenic or tumor fore-
ground sets as well as motifs with common enrichment in both
progression states. In 5 of 6 foreground sets, POU motifs were
more strongly associated with the transgenic state than with the
tumor state (Figure 6A–E). This difference was most pronounced
in analyses of downregulated (Figure 6A) and specific downreg-
ulated gene sets (Figure 6B), where dots representing POU
matrices (blue diamonds) are located far away from the mass of
points. Notably, sites of some POU motifs were also more than 2-
fold enriched in promoters of downregulated genes in tumor. Oct1
matrices were the top ranked motifs in downregulated and specific
downregulated genes in tumor (Table S4). However, promoters of
upregulated genes were detectably enriched with POU sites in the
transgenic state only (Figure 6C–E). These results suggest that
Figure 4. Network of upregulated signaling components in transgenic cells. Red nodes: only in transgenic network; Light red: fold change
was at least +2 higher than in tumor; Light green: fold change was at least - 2 lower than in tumor, Blue: upregulated molecule with similar fold
change in transgenic and tumor. Please, see text for further description.
doi:10.1371/journal.pone.0017738.g004
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state. Furthermore, their activity may represent a major cause of
observed downregulation events. Among the POU transcription
factors represented by matrices identified in the analyses, the
expression profile of Pou5f1 (Oct4) resembled well the observed
progression-state specific enrichment of its binding sites (Table S5).
The Pou5f1 gene exhibited a high fold change (2.75) in the
transgenic state, which had decreased in the tumor state (fold
change 1.70). Indeed, the Pou5f1 gene is specifically expressed in
embryonic stem cells and in tumor cells, but not in cells of
differentiated tissues [15]. Transcription factors with a Forkhead
domain also showed association with the transgenic state. This
signal was best observed in upregulation and cell cycle gene sets
(Figure 6Cand E), yet subtle enrichment in transgenic promoters
could also be detected in specific downregulation (Figure 6B) and
specific upregulation, where the FREAC2 motif ranked among the
top 15 PWMs (Table S4). In the upregulation set, Foxd3 binding
sites showed the strongest signal after Oct1 sites (Table S4). This
would support a potential role of Oct4, as corepression through
overlapping binding sites of Oct4 and Foxd3 was previously
reported [16]. According to expression measurements, Foxd3 was
potentially downregulated in both progression states (Table S5),
although measured expression differences were not statistically
significant. Instead, Foxc1 expression parallels the stronger
enrichment of Forkhead binding sites in transgenic promoter sets,
as it is specifically upregulated in the early progression state
(Tables S1 and S5).
Promoters of upregulated genes in tumor were associated with
binding sites of cell cycle regulators such as AP1-like factors,
STAT, and E2f (Figure 6C–E), of which Atf3, Jun, and E2f3 were
significantly upregulated in both transgenic and tumor cells
(Tables S1 and S5). This finding supports the stronger regulation
of cell cycle processes in tumor detected by comparative GO
analysis. The analysis of cell cycle gene promoters suggests E2f
factors as the most important regulators in both states, whereas a
tendency towards higher q-values in the tumor set was observed
for several E2f motifs (Figure 6E). Notably, the Myc-associated
zinc finger protein was detected in the transgenic cell cycle gene
set (Tables S4 and S5), which indirectly suggests that Myc
impacted cell cycle regulation in transgenic cells, but not or to a
lesser extent in tumor cells. This would be supported by the
expression profile of Myc with significant upregulation in the early
state and subtle or absent upregulation in tumor.
Finally, the lipid metabolism gene sets show strong association
of HNF6 (Onecut1) and PPAR-gamma with the tumor state
(Figure 6F). Of these, HNF6 was significantly downregulated in
tumor, whereas PPAR-gamma exhibited a progression state
specific profile with downregulation in the transgenic state and
significant upregulation in tumor.
While many of the aforementioned transcription factors are
well-known proto-oncogenes, such as Jun, Myc, or E2f3, and the
link between HNF6, PPARgamma and lipid metabolism is
comprehensible, other factors revealed by our analysis are novel
with respect to their role in liver carcinogenesis. Binding sites of
Kaiso (Zbtb33) were most strongly overrepresented in downreg-
ulated tumor genes. Kaiso was shown to silence tumor suppressor
genes in colorectal cancer [17], and its role in cancer was
previously reviewed [18]. Furthermore, motifs of HMG box
Figure 5. Network of upregulated signaling components in tumor cells. Red nodes: only in tumor network; Light red: fold change was at
least 2 points higher than in transgenic cells; Light green: fold change was at least 2 points lower than in transgenic cells, Blue: upregulated molecule
with similar fold change in transgenic and tumor. Please, see text for further description.
doi:10.1371/journal.pone.0017738.g005
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17738Figure 6. Enrichment of TF binding sites in transgenic and tumor DE gene sets. Each dot represents one TRANSFAC binding site
(=sequence motif) positioned by fold enrichment in transgenic (x-axis) and tumor (y-axis) foreground sets. Quantile values greater than 1 indicate
binding site enrichment. Several motifs are highlighted which were shifted away from the diagonal suggesting different importance of
corresponding TFs for regulation in either transgenic or tumor states. Please, see text for further description. A) Analysis of binding site enrichment in
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tion (Figure 6A, LEF1 PWMs) and specific upregulation
(Figure 6D, Sry). While the Lef1 gene was moderately upregulated
in transgenic and tumor cells (Table S5), Tcf7 showed significant
upregulation in tumor. Also, Tcf7l2 appeared to be induced in
tumor compared to its expression level in transgenic cells (Table
S1). All in all, Tcf7 and Lef1 factors are known to play a role in
Wnt signaling, which indicates a connection between these TFs
and Kaiso target genes [18]. Moreover, Wnt signaling components
and the HMG box factor Sox2 were previously implicated in
Oct4-dependent transcriptional networks [19]. Hence, these
findings suggest an EGF-induced mechanism of dedifferentiation
and establishment of stem cell-like properties, which may have
been driven by Oct4 on the level of transcription. The
carcinogenetic mechanism may therefore share similarities with
embryonic stem cell signaling pathwaysf, which was further
supported by enrichment of developmental pathways in Gene
Ontology analysis.
Key node network analysis reveals a key role for IGF-2
signaling in carcinogenesis
Given transcription factors whose binding sites were enriched in
transgenic or tumor gene sets, we sought upstream regulators of
these TFs that may contribute to their activation or inhibition
through signal transduction pathways. We extracted TFs linked to
overrepresented TRANSFAC motifs (Table S4, underlined PWM
names) and subjected resulting TF sets to key node analysis.
Network analyses were carried out separately for transgenic and
tumor. Again, we compared transgenic and tumor results. We first
calculated the empirical cumulative probability P(X$x), in the
following denoted ECP, for each key node. For this, key nodes
reported by ExPlain were ranked by their key node score (see
Material and methods). The ECP of a key node was then
computed on the basis of its rank among all key nodes. Figure 7
shows a plot of log-ECP differences (tumor-transgenic) against
differences of log-Fold change values (tumor-transgenic). Dots
representing key nodes with strongest difference in importance for
transgenic or tumor TF sets are located far away from the ordinate
origin. Fold change differences were depicted on the abscissa.
Notably, components of the EGF signaling network, Adam10, a
metallopeptidase that processes EGF, and Grb2, an adaptor
protein that binds directly to the EGF receptor, exhibited a greater
importance for transgenic than for tumor TFs (Figure 7, blue dots).
We also highlighted EGF, which occupied a less extremal position
(Figure 7, light blue dot). Here we find IGF-2 as tumor-associated
key node, whose location reflects both a greater importance for
all down regulated genes B) Analysis of binding site enrichments in specifically down regulated genes of either transgenic or tumor states C) Analysis
of binding site enrichment in all up regulated genes D) Analysis of binding site enrichments in specifically up regulated genes of either transgenic or
tumor states E) Analysis of binding site enrichments in up regulated cell cycle genes F) Analysis of binding site enrichments in down regulated lipid
metabolism genes.
doi:10.1371/journal.pone.0017738.g006
Figure 7. Plot of expression fold changes versus score statistics of key nodes. Each dot represents one key node found upstream of
transcription factors identified by promoter analysis. Coordinates are the difference of log-Fold changes (x-axis) and the difference of log-probabilities
of key node scores (y-axis). Higher values correspond to higher expression or higher rank of the key node score, respectively, in the tumor state.
Components of the EGF pathway were associated with the transgenic state (blue dots), whereas Igf2 is associated with the tumor state with respect
to both expression and key node score difference.
doi:10.1371/journal.pone.0017738.g007
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(Figure 7, red dot). IGF-2 is a ligand of the insulin receptor as well
as the insulin-like growth factor 1-receptor (IGF-1R). Notably, the
shift of IGF-1, another IGF1-R ligand, also indicated association
with the tumor state, yet the IGF1 gene was potentially
downregulated in tumor cells (data not shown).
To examine the role of IGF-2 signaling as a surrogate for EGF, we
superposed the key node/TF networks of Adam10, Grb2 and EGF
with the IGF-2 network (Figure 8). The merged network shows that
IGF-2 may at least in part substitute for EGF signaling (white nodes
are shared by IGF-2 and EGF pathways). Although in that network
AKTcascadesareonlyconnectedtoEGF-specificpathways,IGF-1R
is also known to activate AKT [20]. Recalling that EGF was
downregulated and IGF-2 was strongly upregulated in tumor cells,
the level of IGF-1R dysregulation may represent a switch that marks
the onset of malignant transformation. This is further supported by
evidence that tumor cells utilize IGF-1R signaling as a survival
mechanism that renders them independent of EGF signals [21].
Notably, our findings suggest an interplay between EGF and IGF-2
pathways already at early stages of carcinogenesis.
Analysis of TF co-occurrences in promoters of
upregulated tumor genes
To further investigate the EGF-induced switch from transgenic
to tumor state, we performed another step of promoter analysis,
where we focused on TFs, whose regulation of activity can be
mechanistically explained by signal transduction cascades down-
stream of an EGF receptor ligand or an EGF receptor. Hence, our
goal was to identify EGF-dependent transcription regulators that
could exert the switch from the transgenic to the tumor state.
Therefore, we sought TFs downstream from EGF whose binding
sites were enriched in promoters of upregulated tumor genes. This
was done using the key node functionality of ExPlain. Co-
occurrence analysis of TF binding sites was chosen to achieve
higher specificity in selecting potentially regulated promoter
regions in foreground and background sets than is possible by
considering individual PWMs only.
We retrieved all TFs that were inferred in the signal
transduction network downstream from the EGF ligands and
receptors: HB-EGF, EGF, ErbB1, ErbB2, or ErbB3. In addition,
we included PWMs of upregulated tumor factors. TRANSFAC
matrices linked to all such TFs were used for further analysis. In
total, we obtained 266 ‘‘tumor-EGF-network’’ PWMs yielding
31,306 pairwise combinations. To avoid pairs of similar matrices,
we considered only combinations of PWMs, which overlapped in
less than 10% of the hits of the PWM with the lower total number
of matches at a score P-value threshold of 0.001. Score P-values
were estimated on the basis of predictions in promoters of the
background subset. As a result, 34 and 45 PWM pairs were
reported at a P-value below 10
23 in the tumor complete and
specific gene sets, respectively. Identified pairs grouped by TF
classes are provided in Table S6.
The TF pair analysis results provide evidence for involvement of
several upregulated TFs such as Atf3, E2f3, Egr1, Fos, Hnf1b, Jun,
Maff, Mef2a, Nfe2, Nfe2l3, Nr2f1 or Nr2f2, Pbx3. Pparg, Smad3,
and Tcf7. These factors were found in different combinations in the
pair analysis (Table S7). We additionally found overrepresented
pairsofMEFwith theknownprotooncogene c-Myb.MEFmediates
G1-S mitotic transition, erythrocyte differentiation, and regulation
of myeloid cell differentiation. It is known to be upregulated in
breast cancer as well as several other neoplasms. C-Myb was
previously shown to cooperate with various other transcription
factors such as factors from the Ets family but also with C/EBP and
AML factors [22]. In our analysis we detected co-occurrence of
Myb binding sites and HNF4/COUP bindings sites (Table S6).
Notably, the Myb – COUP-TF pair was predicted in the promoter
of the Igf2 gene, which was significantly upregulated in the tumor
conditions (Figure9).We thinkthat indeedupregulationof this gene
canbeexplainedbya transactivationeffect ofc-Mybcombinedwith
the potential competitive substitution of the tumor downregulated
HNF4 factor by COUP-TF1. The COUP-TF1 gene (Nr2f1) was
upregulated in transgenic and tumor in comparison to the normal
tissue according to gene expression measurements (fold changes
6.26 and 2.62 in transgenic and tumor, respectively). The
antagonistic competition of HNF4 with COUP-TF factors for the
same promoter element has been described before, e.g. for human
ApoCII [23] and for human EPO [24].
Analysis of multiple combinations of TF binding sites in
promoters of upregulated and downregulated genes in
tumor
Synergistic binding of multiple transcription factors to certain
combinations of binding sites is an important mechanism of
achieving highly specific regulation of genes in particular cellular
conditions. We can hypothesize, that tumor cells are characterized
by particular pattern of activated transcription factors, which
enabled them to evolve from pre-tumor to tumor state by escaping
multiple checkpoints and by establishing signal independent
uncontrolled proliferation. We sought to identify such patterns of
multiple activatedtranscriptionfactors,which synergisticallybindto
their target genes and may be responsible for the transgenic-tumor
switch. For this, we focused our attention, first of all, on genes
specifically upregulated in tumor compared to transgenic state, that
encodecomponentsoftherevealedEGFandIGF-2pathways.Such
genes can provide complex feedback mechanisms in the network
helping to maintain the tumor status of the cells. All highly
upregulated genes (log-Fold change in tumor . 2.0) were mapped
on the TRANSPATH network and signal transduction chains
propagating the activation signal downstream to transcription
factors were constructed using ExPlain tools. Among the compo-
nents of such downstream signal transduction network we identified
12 proteins whose genes switched expression in the transgenic-
tumor transition (transgenic fold change , tumor fold change). We
speculate that the change of expression of these 12 genes in tumor
compared to transgenic contributes to self-maintenance of the
tumor state, and the set of transcription factors regulating activity of
these genes might be the best candidates for understanding the
regulatory mechanism of this switch. In addition, we analyzed 34
genes, that were downregulated in tumors compared to transgenic
state and that were associated with the most significantly
downregulated functional category ‘‘organ development’’ as
revealed by GSEA analysis. We analyzed promoters of these
upregulated and downregulated genes using the ExPlain tool in
order to reconstruct maps of multiple TF binding sites in promoters
of these genes, which could help us to understand the molecular
mechanisms of the switch to the tumor state. TF site maps of
upregulated gene promoters are depicted in Figure 10. It is obvious
that most of the promoters are characterized by similar composition
of TF binding sites, although, their mutual location and position in
the promoters relative to the start of transcription can vary
significantly between different promoters.
Western blotting and DNA binding activity of networked
transcription factors at gene specific promoters
A total of 5 upregulated and 14 downregulated genes were
selected based on highest scores for predicted TF binding sites
while EMSA band shift assays were carried out with specific
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shown in Figure 11A Western blotting experiments with nuclear
extracts of tumor tissue revealed highly significant repression of
HNF4alpha, while DNA binding activity of this Zn-finger protein
was evidenced at gene specific promoters of EGF, Foxc1, Nfsf1and
Defrc6. Here, the DNA binding activity varied, when individual
promoters were analyzed but recapitulate the findings from the
Western blotting experiments, i.e. the HNF4alpha binding activity
followed the order . transgenic without tumor . non-transgenic
and tumor extracts, respectively. Likewise, expression of the
Figure 8. Merged key node networks of EGF and IGF-2 cascades with transcription factors revealed by promoter analysis. Blue
nodes: EGF-specific network components, Red: IGF-2-specific network components, Light blue: Key nodes of the EGF pathway, Yellow: IGF-2.
doi:10.1371/journal.pone.0017738.g008
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repressed with nuclear extracts of tumor tissue (see Figure 12A)
while EMSA band shift (Figure 12B) assays confirmed its binding
at gene specific promoters of Cav1, Foxc1, Defrc6, Itga4, EGF,
Nr3c1,Sprr2i, TH and Zbtb7b, albeit at different levels. Notably,
little to none DNA binding activity was observed with nuclear
extracts of tumor tissue. Furthermore, the DNA binding activity of
c-Myb was studied. As shown in Figure 13A its expression was
significantly reduced in nuclear extracts of tumor tissue of two of
the three individual animals investigated, but its DNA binding
activity appeared to be particularly reduced at gene specific
promoter sequences of BMP7 but less so at predicted TF binding
sites of PPARg and Igf2. Very significant regulation was also
observed for STAT5 with almost none detectable expression levels
in nuclear extracts of tumor tissue even though one non transgenic
control animal also displayed very low levels of this transcription
factor (Figure 14A). Consequently, its DNA binding activity at
gene specific promoter sequences of the transcription factor
PPARg was nearly non detectable (Figure 14B). As observed with
other transcription factors (see above) expression of ETS was
repressed in nuclear extracts of tumor tissues (see Figure 14C)
while its DNA binding activity was hardly measurable at predicted
TF binding sites at gene specific promoter sequences of Igfbp6
(Figure 14D). The expression and DNA binding activity of the
transcription factor Mef2 was also investigated (Figure 15A). Here
Western blotting experiments confirmed strong regulation of this
protein in transgenic but non-tumor bearing mice but in EMSA
band shift assays addition of the antibody resulted in a strong band
in the pocket of the gel particularly with nuclear extracts of
transgenic animals and less so with those of tumor tissue while with
non-transgenic controls no band shift could be observed
(Figure 15B). Similarly, expression of GR was repressed in nuclear
extracts of tumor bearing mice (Figure 15C) while its DNA
binding activity was similar at a gene specific promoter sequence
of the CAV gene (Figure 15D). Regulation of the p53 protein was
also investigated and found to be strongly induced in transgenic
but non-tumor bearing mice where as its expression was similar
with nuclear extracts of control and tumor bearing mice
(Figure 16A). Here, DNA binding activity at gene specific
promoters of Xlr, Nr2f1, Zbtb7b, Sprr2i, Ffg18 and ERBB3 was
observed with nuclear extracts of transgenic and tumor bearing
mice but the overall activity varied considerably (Figure 16b) with
no obvious trend. Finally, expression of the hepatic nuclear
transcription factors and of COUP-TF was studied. Notably,
several of the liver enriched TFs were repressed in nuclear extracts
of tumors as were COUP-TFI and II (see Figure 17).
Discussion
This study aimed at an improved understanding of molecular
events associated with EGF-induced, nongenotoxic hepatocarcin-
ogenicity. We report on results of computational as well as
experimental analyses carried out on gene expression profiles of
successive disease stages, which we described previously [1]. In the
course of this work clinical and biological aspects of observed
expression changes were examined. Pre-tumor and tumor state
expression of 39 known liver cancer biomarkers disclosed
possibilities to refine their application as pre-tumor and tumor
Figure 9. Putative binding sites for c-Myb and HNF4/COUP-TF transcription factors in the promoter of the Igf2 gene. Regulation of
Igf2 gene can be explained in part by the binding of c-Myb to its recognition site in the promoter of this gene.
doi:10.1371/journal.pone.0017738.g009
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tumor-specific differential expression which was reverted in the
tumor state, whereas Ccnd1, Gpc3, Mvk, Pparg, Rbl2, Robo1
were only upregulated in tumors. The adverse regulation of Pparg
combining pre-tumor downregulation with upregulation in tumor
invites further investigation as a liver cancer biomarker that
supports distinction of three different biological conditions.
Comparison of GO biological enrichment and network
cluster analysis
To further elucidate the biological and molecular functions
targeted by expression responses, we analyzed associations
between GO biological processes and DE genes in transgenic
and tumor cells and constructed network clusters, which
connected signaling molecules in pathways with a minimal
proportion of differentially expressed components. Since we
noticed that genes were often detected in only one progression
state by statistical differential expression analysis while fold
changes indicated a difference to the normal condition in both
states, we constructed so-called extended gene sets to reduce the
effect of false negative findings in the statistical analysis step. This
was done in a careful manner by taking detection of differential
expression in one progression state as evidence for the other and
included a gene in the extended set if the detected microarray
probe set suggested more than 2-fold expression change. By this
process we obtained enlarged up- and downregulated gene sets,
which eliminated some differences seen otherwise and led to a
more stringent definition of specific up- or downregulation. This
was in line with our goals to perform comparative analyses of GO
category enrichment and to compare clusters of differentially
expressed signaling molecules, where we sought to minimize the
possibility of falsely identifying differences.
Comparison of GO biological enrichment pinpointed regulation
of genes involved in cell cycle, developmental pathways, lipid
metabolism, and protein deubiquitination. Other scientific works
supported our findings. In contrast to cell cycle and developmental
categories whose enrichment in both transgenic and tumor gene
sets reflects progressive regulatory alterations during carcinogen-
esis, downregulation of genes associated with protein deubiquiti-
nation, a relatively new target for cancer therapy, was first
observed in tumor cells. Focusing analyses on the identified
cellular functions could thus help to further dissect the causal
mechanisms of switching from pre-tumor to tumor state. A first
step in this direction was undertaken in this work by analyzing and
comparing overrepresentation of transcription factor binding sites
in promoters of cell cycle as well as lipid metabolism gene sets as
further discussed below.
The interplay of differentially expressed signaling molecules
was examined in more detail by network analysis. ExPlain
generated the network clusters in a data driven process, which is
guided by the specified input set of molecules. The resulting
clusters represent context-specific subdistricts of the entire
cellular network, which are densely populated with molecules
targeted by observed expression changes. The network clusters
constructed for upregulated transgenic and tumor molecules
connected components of growth factor signaling, cell cycle
regulation, as well as chemokine and cytokine signaling. We
assume that the interplay of molecules with different canonical
functions provides for a realistic view on cellular control
mechanisms. These are implemented by a cellular network that
connects thousands of molecules, many of which exert a
regulatory role in a multiplicity of biological contexts. Compar-
ison of transgenic and tumor networks supported our hypothesis
of progressive alterations of cell cycle regulation as well as of
lipid metabolism during hepatocarcinogenesis. Moreover, this
analysis yielded testable hypotheses about relevant molecular
cascades involving p107, p130, and p15INK4b as well as
survivin, Cdk1, cyclin B1, Plk1, and Bub1. In the transgenic
Figure 10. Maps of predicted binding sites of selected TRANSFAC weight matrices in promoters of genes up- or downregulated in
tumours versus transgenic cells.
doi:10.1371/journal.pone.0017738.g010
Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 13 March 2011 | Volume 6 | Issue 3 | e17738network we found a cascade of molecules regulating cell
migration and adhesion, which included VCAM-1, alpha4-
integrin, TSP-1, and IAP. This finding complied with decreased
enrichment of cell motility components in tumor revealed by GO
analysis. Hence, the constructed network clusters complemented
the results of our GO analysis by facilitating detailed insight into
the molecular pathways targeted by carcinogenic expression
changes. Taking into account the presence of EGF-receptors
ErbB1-3 in both transgenic and tumor clusters, the networks
reveal in addition how components of biological processes
proposed by GO analysis were tied to EGF-signaling in the
context of hepatocarcinogenesis.
Figure 11. Western blotting and EMSA for HNF4a.AWestern blotting of HNF4a with nuclear protein extracts isolated from liver tissue of non-
transgenic, transgenic and tumour tissue B EMSA confirmation experiments at gene specific promoter sites of EGF, Foxc1, Nf2f1 and Defrc1.
doi:10.1371/journal.pone.0017738.g011
Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e17738Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 15 March 2011 | Volume 6 | Issue 3 | e17738Reconstruction of regulatory causes of EGF-induced
hepatocarcinogenicity
After elaborating on downstream effects of EGF-induced
tumor development, we reconstructed causes of observed
expression changes. First, we analyzed overrepresentation of
transcription factor binding sites in promoters of upregulated and
downregulated transgenic as well as tumor gene sets. For this part
of the work, we developed a novel statistic for binding site
enrichment analysis that compares foreground/background
binding site proportions with promoter proportions and quanti-
fies overrepresentation with the ratio quantile of corresponding
Beta distributions. The statistic was proposed for several reasons.
PWM-based binding site prediction typically requires specifica-
tion of a score threshold that determines true and false positive
rates. In a comparative method, e.g. like F-MATCH, the
threshold at which a weight matrix optimally detects overrepre-
sentation is usually not known a-priori. Therefore, F-MATCH
adopts the strategy of iterating over score thresholds to optimize
the overrepresentation of predicted binding sites for each
specified PWM. However, at low score cut-offs, where high
numbers of binding sites are predicted in foreground and
background promoters, statistical tests like the exact binomial
test can report highly significant P-values for small ‘‘fold’’
differences when these are supported by high counts of binding
site instances. Consequently, one cannot start from arbitrarily low
PWM score thresholds in order to find the best, most likely higher
cut-off. Eventually, one might also like to prioritize binding site
motifs and would naturally assign highest priority to motifs with
strongest enrichment. In this case, simply calculated odds ratios
may result in a different ordering of motifs than corresponding
enrichment P-values. We therefore developed an approach that
focuses on the magnitude of overrepresentation expressed as a
Figure 13. Western blotting and EMSA for cMYB. A Western blotting of cMYB with nuclear protein extracts isolated from liver tissue of non-
transgenic, transgenic and tumour tissue B EMSA confirmation experiments at gene specific promoter sites of BMP7, PPARc and IGF2.
doi:10.1371/journal.pone.0017738.g013
Figure 12. Western blotting and EMSA for CEBPa.AWestern blotting of CEBPa with nuclear protein extracts isolated from liver tissue of non-
transgenic, transgenic and tumour tissue B EMSA confirmation experiments at gene specific promoter sites of CAV1, Foxc1, Defrc1, ITGA4, EGF,
Nr3c1, Sprr2i, TH and Zbtb7b.
doi:10.1371/journal.pone.0017738.g0112
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promoter sequences in foreground and background gene sets.
This quantity cannot be trapped by highly significant P-values
associated with small odds ratios, because it focuses on a
(statistically corrected) estimate of the odds ratio itself. Finally,
we assume that the proposed statistic enables more intuitive
prioritization of motifs by expressing their importance as ’’relative
enrichment’’ in foreground promoters. It may however by
perceived as potential drawback to specify the quantile interval
as a free parameter, which was set here to 1%.
In this study, we applied the new promoter analysis method to
transgenic and tumor promoter sets and subsequently compared
the results of both progression states. Similar to comparison of GO
analyses, this setup enabled us to not only identify highly enriched
binding sites in promoters of DE genes, but also to observe
differences in importance of certain motifs for transgenic and
tumor gene sets. As described in the results section, promoter
analysis supported stronger regulation of cell cycle and of lipid
metabolism in the tumor state by associating motifs of Atf3, Jun,
E2f3, and Pparg with corresponding tumor genes and thus
Figure 14. Western blotting and EMSA for STAT5 and ETS2. A Western blotting of STAT5 with nuclear protein extracts isolated from liver
tissue of non-transgenic, transgenic and tumour tissue B EMSA confirmation experiments at gene specific promoter sites of PPARc C Western
blotting of ETS2 with nuclear protein extracts isolated from liver tissue of non-transgenic, transgenic and tumour tissue D EMSA confirmation
experiments at gene specific promoter sites of Igfbp6.
doi:10.1371/journal.pone.0017738.g014
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study revealed overrepresentation of POU motifs predominantly
in transgenic promoter sets. Expression profiles of POU factors as
well as of HMG and Forkhead factors whose motifs were also
identified through promoter analysis led us to propose Oct4
(Pou5f1), Tcf7, Lef1, and Foxc1 as regulators of a transcriptional
network potentially under control of Wnt signaling. We speculate
that the factors contribute to regulation of developmental
pathways, which were enriched in both up- and downregulation
according to GO analysis. Although network analyses carried out
in this work did not reveal a link between Oct4 and EGF-signaling
on the level of protein-protein interactions, in-vivo binding
fragments for c-Myc, c-Jun, and c-Fos were previously located in
the vicinity of the human POU5F1 gene [25] and provide for a
possible explanation for EGF-induced transcriptional activation of
Oct4. Altogether, overrepresentation of binding sites in promoters
of DE genes detected biologically meaningful transcription
regulators, which further support the results of other parts of this
study. Subsequent analysis of key nodes upstream of transcription
factors predicted for transgenic and tumor promoter sets revealed
a switch from EGF signaling in the pre-tumor state to IGF-2 in the
tumor state. Indeed, EGF expression was significantly downreg-
Figure 15. Western blotting and EMSA for MEF2 and GR. A Western blotting of MEF2 with nuclear protein extracts isolated from liver tissue of
non-transgenic, transgenic and tumour tissue B EMSA confirmation experiments at gene specific promoter sites of TH C Western blotting of GR with
nuclear protein extracts isolated from liver tissue of non-transgenic, transgenic and tumour tissue D EMSA confirmation experiments at gene specific
promoter sites of CAV1.
doi:10.1371/journal.pone.0017738.g015
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components such as BTC and ErbB3 were decreased in tumors
compared to transgenic cells. Furthermore, the overlap of EGF
and IGF-2 pathways, as demonstrated by merging both networks
into a single pathway, could enable IGF-2 to take over the
functional role of EGF and thus render the tumor cell independent
of EGF signaling. By the same mechanism cancer cells may
acquire resistance to EGF pathway inhibitors.
To further examine the molecular causes of EGF-induced
malignant transformation, we searched promoters of upregulated
tumor genes for pair wise combinations of TF binding sites. Paired
site searches started out from individual site predictions adjusted to
a P-value of 10
-4. We used actual promoter sequences to estimate
respective PWM score thresholds corresponding to the chosen
background frequency. However, promoter sequences contain
both functional and non-functional binding sites. Moreover, the
proportion of functional sites among all predicted sites is expected
to increase with higher, more stringent PWM scores, so that the
background frequency of site predictions could be overestimated
by using sequences of regulated genes. Yet, gene expression data
allow for selection of sequences in which binding sites should occur
at a background rate in the context of the particular biological
condition. Thus, we composed background sets of genes with
unaltered expression in the tumor state to adjust score cut-offs. In
order to focus our analysis on TFs whose activity can be
modulated by EGF signaling, we selected motifs of TFs
downstream of EGF according to network analysis and of TFs
upregulated in the tumor state. As a result, we obtained
significantly enriched (P-value ,0.001) pairs of TRANSFAC
motifs representing several upregulated and EGF-associated TFs.
The set of weight matrices selected by co-occurrence analysis was
subsequently used as starting point to derive more complex
promoter models. Although Fisher test P-values indicated
enrichment of several PWM pairs at the chosen significance level,
we noticed that each particular combination was present in only
few promoters. We attribute this to the stringent threshold that
was imposed on individual binding site predictions. Furthermore,
we assume that the foreground sets comprised promoters
controlled by a number of different regulatory processes, so that
higher order TF combinations were more suitable to describe
subsets of coregulated promoters.
Based on more complex TF modules, we selected a small set of
factorsfor experimentalvalidation.Results of the EMSAanalysis are
provided in Table S8. Western blotting and EMSAs demonstrated
that c-Myb was upregulated in EGF-transgenic animals and in
tumors. Notably, c-Myb is well known for its oncogenic potential
and was the subject of targeted therapies in various cancers [26]. We
also investigated DNA-binding activity of c-Myb on novel predicted
genetargets.Theseincluded Bmp7,Ppargand Igf2,allofwhichplay
an important role in cancer biology. Indeed, PPAR-gamma
antagonists are clinically evaluated for their anti-tumor growth
activity in liver cancer. It is of considerable importance, that c-Myb
regulates Igf2 (Figure 9), which allows tumor cells to develop an
independent autocrine loop thereby integrating EGF and IGF-2
signaling networks [27,28]. Additionally, IGF proteins are primarily
produced in the liver to act as an important pro-survival factor as
shown in a number of cancer cell lines.
Figure 16. Western blotting and EMSA for p53. A Western
blotting of p53 with nuclear protein extracts isolated from liver tissue of
non-transgenic, transgenic and tumour tissue B EMSA confirmation
experiments at gene specific promoter sites of Xlr, Nr2f1, Zbtb.7b,
Ffg18, Sprr2i and ERBB3.
doi:10.1371/journal.pone.0017738.g016
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enrichment in genes regulated in HCCs. Several studies have
demonstrated an important role of STAT5 in liver fibrosis and
cancer development through TGF-beta and STAT3 activation.
We observed loss of STAT5 protein expression in HCC and
demonstrated STAT5 DNA-binding activity in Igfbp6 (Table S8).
Indeed, loss of STAT5 causes liver fibrosis and cancer
development as recently reported by Hosui et al. [29]. Our
computational analyses revealed Igfbp6 to be a target of Stat5 as
evidenced by EMSA band shift assays. Recent evidence suggests
Igfbp6 to induce cell migration of cancer cells that could be
repressed by inhibitors of p38 and ERK1/2 MAPK signaling
[30]. Additionally, early studies demonstrated Ets gene regulation
in cancer and that overexpression of Ets causes cellular
transformation in-vitro as well as in-vivo. The emerging role of
ETS in human cancer has recently been reviewed and ETS
regulated biological pathways will provide novel opportunities for
better diagnosis and staging of disease as well as for the
development of anti-cancer therapies [31]. Note, we show Ets-2
DNA-binding for Igfbp6 (Table S8) and therefore identified two
Figure 17. Western blotting of liver enriched transcription factors with nuclear protein extracts isolated from liver tissue of non-
transgenic, transgenic and tumour tissue.
doi:10.1371/journal.pone.0017738.g017
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mitogenic IGF proteins.
Furthermore, we detected regulation of genes by C/EBPalpha.
Overall we examined 9 novel gene candidates targeted by C/
EBPalpha. Strikingly, all TFBS could be confirmed by EMSA
band shift assay and in Western blotting experiments with nuclear
extracts of tumor liver tissue C/EBPalpha was significantly
repressed. This agrees well with its function as a key regulator of
p21. Indeed cell cycle progression is regulated, at least in part by
protein-protein interaction of C/EBPalpha with p21. It is of no
surprise that tumors display less C/EBPalpha expression and we
found all novel gene targets of C/EBPalpha to be repressed in
tumors (Table S8).
Finally, there is a wealth of information on the role of p53 in
liver cancer. Here, we demonstrate p53 binding sites in genes
encoding components downstream EGF/IGF-2. Notably, p53 was
still identified by promoter analysis although its expression level
was similar to normal controls.
In order to summarize the results obtained in this study we have
build a hypothetical model-diagram of the EGF/IGF-2 regulatory
circuit functioning during the transition from transgenic to tumor
state (Figure S2). This model combines two signal transduction
networks of the signal flow from EGF and IGF-2 reaching a
number of transcription factors (identified by combined promoter
and network analysis and validated experimentally), that in turn,
regulate expression of several important genes (validated using
EMSA assays) that encode components of the upstream network.
Thus created feedback loops should play an important role in
emerging as well as in stabilizing the cancer state of the cells, In
this model, we can propose multiple paths of signals initially
coming massively from EGF in the transgenic cells and triggering
activity of several TFs, such as C/EBP-alpha, GR and HNF-
4alpha, that down-regulate expression of their target gene
encoding EGF (Egf) as well as Cav1, thus trying to compensate
the excess of the EGF stimulus in the cell. At the same time,
through parallel signaling cascades and activation of a number of
other TFs, such as c-Ets-1, PPAR-gamma, STAT family factors, c-
Myb and others, upregulation of expression of Igf2 gene as well as
Igfbp6 and Pparg can be achieved. Due, to several feedback loops
on different levels of the network coming from these genes, we can
speculate that a steady signal for upregulation of the Igf2 gene
leads eventually to a sharp elevation of its expression with the
consequence of increase of mitogenic activity of the cells, which
marks the transition to the carcinogenic state. It was reported
previously, that Igf2 gene is located in an imprinted area of
genome and is repressed in most of tissues of the adult organism
[32]. Loss of imprinting of the Igf2 gene is one of the most
common observations in cancers [33]. It was shown that the
imprinting status is maintained by binding of CTCF repressor to
an intergenic area of the Igf2 gene and loss of this binding can lead
to 10-fold elevation of Igf2 expression [34]. We propose a model
where the feedback mechanisms involved in the Igf2 epigenetic
control through multiple transcription factors, activators and
repressors, play the major role in the switching the cells to
malignant transformation.
In conclusion, promoter analysis of the differentially expressed
genes enabled us to identify transcription factor binding sites. Such
integration of sequence information into signal transduction
networks enabled an identification of key nodes upstream of the
identified transcription factors. By searching for pairs of TF sites
and integration of this information into the network analysis robust
information can be retrieved in an unbiased manner that clearly
identifies keynodes and molecules acting in concert in defined
biological conditions. Therefore, we propose a sequence of events
whereby the insulin-like growth factor (IGF) pathway represents
an important molecular switch in malignantly transformed liver
cells. Possibly, an initial upregulation of EGF is followed by a
subsequent and sustained activation of IGF2 signaling cascades.
Overall, we hypothesize a switch in autocrine signaling to foster
tumor growth that was initially triggered by EGF. In this regard c-
Myb is considered to be an important factor of the IGF2 positive
feedback loop. Notably, we identified c-Myb binding sites in the
promoter IGF2 gene and c-Myb to be a downstream partner of
the IGF2 signaling cascade. Therefore our analysis demonstrates
the knowledge gain form promoter analysis combined with
upstream key node identification.
Materials and Methods
Ethics Statement
All animal work followed strictly the Public Health Service
(PHS) Policy on Humane Care and Use of Laboratory Animals.
Formal approval to carry out animal studies was granted by the
ethical review board of Hannover/Lower Saxony, Germany
(‘‘Niedersa ¨chsische Landesamt fu ¨r Verbraucherschutz und Le-
bensmittelsicherheit (LAVES)’’, http://www.laves.niedersachsen.
de). The approval ID is Az: 33.9-42502-04-06/1204.
Gene expression profiles of IgEGF-overexpressing murine
hepatocytes in transgenic and tumor state
We analyzed gene expression data from murine primary
hepatocytes in normal cells as well as different states of disease
progression, which were measured on Affymetrix MG_U74Av2
chips. These data were previously described in [1]. For the
purpose of studying mechanisms of tumor onset we focused on a
subset of hybridizations comprising normal (four replicates),
transgenic (three replicates), and small (one replicate from pooled
samples) as well as medium-size (four replicates) tumor states. In
the transgenic condition hepatocytes overexpressed IgEGF, yet
livers presented no detectable tumor, so that respective expression
profiles were considered to present a pre-tumor state. The
Bioconductor method EBarrays [35,36] inferred differential
expression based on MAS 5 processed expression data, separately
comparing transgenic and tumor measurements to the normal
condition. Differential expression was assumed for probe sets if the
respective posterior probability was greater than 0.5 according to
the Lognormal-Normal and the Gamma-Gamma model.
Analysis of gene expression data with ExPlain
Computational analyses used version 2.3 of the BIOBASE
ExPlain system [37,38]. ExPlain integrates genomic information
with biological knowledge bases and computational analysis
methods. As described below, transcription factor binding sites
(TFBSs) were predicted by positional weight matrices (PWMs)
from the TRANSFAC database [39] in murine promoters
specified in the TRANSPro database [40]. The latter resource
provided 61,113 transcription start sites (TSSs) and surrounding
genomic sequences for 24,353 murine genes. TRANSPro defines a
set of reference TSSs for each gene by a weighted combination of
annotations from EPD, DBTSS, Ensembl, and Fantom [41–44].
Information from manually curated databases is given higher
weight than computationally predicted TSS locations. A score is
assigned to each reference TSS according to spatial density and
weights of relevant primary TSS annotations and the reference
TSS with the highest score among several alternative TSSs of a
particular gene is denoted ‘‘best supported’’. Furthermore,
topological analyses of signal transduction networks were per-
formed using molecular reactions collected in the TRANSPATH
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interactions between about 27,000 genes and 86,000 proteins
(enzymes, transcription factors, receptors, adaptor proteins), their
complexes, modified forms, small molecular ligands, and endog-
enous metabolites.
Functional analysis of differentially expressed genes
The Gene Ontology (GO) [46] provides an extensive ontolog-
ical description of cellular components, molecular functions and
biological processes. It is routinely applied in studies to test for
enrichment of categories in sets of genes or proteins. Statistical
significance of enrichment is typically quantified by the one-tailed
Fisher test. The one-tailed Fisher test calculates the probability P(X
$ x) of finding purely by chance at least x out of K genes associated
with a category comprising M genes given a total database size of
N genes (1).
P(X§x)~
X argmin(K,M)
k~x
M
k
  
N{M
K{k
  
N
K
   ð1Þ
To gain insight into functional changes accompanying tumor
development in non-genotoxic hepatocarcinogenesis we compared
enrichment P-values of GO biological process terms calculated for
differentially expressed genes of transgenic and tumor states.
Fisher test P-values were calculated for all GO terms linked to at
least one gene in either gene set or otherwise assigned a value of
1.0. Functional categories were then attributed to the gene set
(transgenic or tumor) achieving the highest significance of
enrichment and ranked by the difference of log10-P-values in
order to guide towards cellular functions most strongly affected by
disease progression.
Identification of key nodes and clusters in signal
transduction network using a graph-topological
algorithm
Signal transduction through a network of molecules is an
important part of the cellular regulatory system. We applied
network analysis methods to elucidate the molecular context of
differentially expressed signaling molecules (network clusters) and
to reconstruct pathways between transcription factors and
upstream regulators of their activity (key nodes). Network
construction in ExPlain implements the Dijkstra algorithm as
core to find the shortest path (minimal cost) tree whose reaction
cascades are weighted by the sum of the involved edge costs. We
initialized the edge costs using three different values. Cost 0 was
used to represent hierarchical classification links between mole-
cules in the database. For direct reactions and indirect reactions
we used cost 1 and 3, resp. A path cost is implicitly defined as the
sum of the costs of its edges.
The network cluster algorithm constructs cascades of maximally
three reactions to connect each pair of input vertices (molecules).
As a result, input molecules are joined into clusters of one or more
proteins linked by corresponding pathways.
In key node analysis, we searched for signaling molecules (key
nodes) and corresponding networks that can transmit a signal to or
receive a signal from several of input molecules within a certain
path cost limit [41]. A key node search starts from each molecule
of an input set Vx and constructs the shortest path to all nodes of
the complete network V within a given maximal path cost dmax (i.e,
the sum of the costs of all edges in the shortest path from a vertex
in Vx to a vertex in V should be smaller than or equal to dmax). The
search can be conducted in reverse direction of the edges leading
to input molecules (upstream) or in the same direction (down-
stream). For each node i of V, the algorithm counts Ni, the number
of nodes of Vx (number of true positives) that can be reached by a
path satisfying dmax. The list of all possible key nodes that can reach
at least one input molecule is sorted according to the specificity
score si.
si~
Ni
1za:Mi
ð2Þ
In equation (2), Mi is the number of molecules in the whole
network, which are reachable from node i within dmax steps, yet are
not part of the input set of molecules (false positives). The
parameter a is a penalty (0,a,1) that adjusts the balance
between true positives and false positives. As described earlier [41],
we empowered the key node analysis by the so-called ‘‘pathway
persistence’’. This extension integrates information about known
canonical pathways and chains of consecutive reactions that were
proven experimentally in order to improve the accuracy of key
node prediction, especially to diminish the false positive error.
Briefly, the modified algorithm gives preference to inclusion of
verified reaction cascades (canonical pathways) into shortest paths
by on-the-fly insertion of additional edges, which represent short-
cuts within verified reaction cascades. The desired effect is that the
key node algorithm not only prefers reactions from the verified
cascades, but at the same time, it is pushed to stay (‘‘to persist’’)
within one cascade as much as possible. The strength of this effect
is adjusted by a parameter h (h [0,1]).
In details, the application of verified cascades (pathways) to the
key node search is done as follows: A pathway P is defined as a
graph GP = (VP,E P,C ), which is a sub-graph of the complete
signaling graph G= (V, E, C). Let SPij be the graph of the shortest
paths between i,j VP within pathway P. Further, let CPij be the cost
of the shortest paths, where CPij = ‘ if SPij = Ø. We combine GP
and G yielding the final graph G’=(V,E’,C’) by introducing
additional edges E’ = E U {(i, j) | SPij ? Ø} and by extending the
cost function for them by C’ = {f(CPij)| f(CPij) # Cij} U {Cij| f(CPij)
. Cij}. As function f we use f(x)=x
h, with h [0,1]. The aim of f is
to make the cost function of any new edge (i, j) sublinearly
dependent from the cost of the corresponding original shortest
path SPij. The effect is that the costs of paths within a known
pathway have decreased due to the cheaper short-cuts. This
algorithm prioritizes the selection of the paths persisting inside
known pathways during the search of the key nodes. The effect is
maximal when h=0 and absent when h=1. Therefore we call h
‘‘rigidity parameter’’ which the balance between rigidity and
sensitivity during the search. As demonstrated earlier, the pathway
persistence has an advantageous effect with regard to sensitivity
and specificity of identifying correct pathway components in a key
node network [41].
Due to the strong connectivity in signaling networks, a key node
search is prone to yield many false-positive key nodes. In this
study, we therefore calculated an empirical cumulative probability
(ECP value) for each key node identified, based on the score rank
of the key node. The ECP value of a key node is calculated as
ECP=RK*1/NK, where, RK is the rank of the key node and NK
is the total number of the key nodes found in the analysis. ECP
estimates a cumulative probability of a given key node to be found
at the rank RK and higher by random chance. We then contrasted
ECP values of key nodes obtained for the transgenic state with
ECP values of key nodes of the tumor state. This was done to
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importance for transgenic and tumor TFs as well as expression
changes and thereby rely less on selection of key nodes based on
statistical error rates. A framework to automatize handling of the
various free parameters required by the key node analysis
algorithm and to estimate false discovery rate using random
shuffling of the input nodes shall be described elsewhere
(manuscript in preparation).
Promoter analysis
Overrepresentation of TF binding sites. We analyzed
overrepresentation of transcription factor binding sites in
promoters of differentially expressed genes and compared the
importance of transcription factors for transgenic and tumor
gene sets. It is well known that promoters of co-regulated genes
are enriched with binding sites of relevant transcription factors
[47]. Several algorithms have been developed that test for the
significance of enrichment of binding sites in promoters of a
gene set of interest (foreground set) compared to a background,
where the background set is often compiled from genes which
are not differentially expressed in the same biological condition
or from randomly sampled genes. For this type of analysis,
ExPlain provides the F-MATCH program described in [41].
The algorithm starts with PWM score thresholds employed in an
initial site search conducted with MATCH [48] and iteratively
increases the threshold of each individual PWM to find a
parameter that produces the most significant enrichment of sites
in foreground promoters. Significance of enrichment is
quantified by the binomial exact test calculated according to
equation (3).
P(X§x)~
X N
n~x
N
n
  
:pn:(1{p)
N{n ð3Þ
Here n denotes the number of predicted sites in the foreground
and N is the total number of sites. The relative proportion of
foreground sequences among both foreground and background
sequences gives the parameter p.H e n c e ,t h eF - M A T C H
algorithm compares the proportion of foreground sites among
all predicted binding sites to the proportion of foreground
promoters among all promoters.
We adopted this strategy to juxtapose the relative importance of
transcription factors (represented by their PWM) for correspond-
ing transgenic and tumor gene sets. Instead of using P-values to
quantify enrichment of binding sites in a foreground promoter set,
we expressed the relative importance of a TF by a probabilistic
estimate of the odds ratio of site and promoter proportions. As in
the F-MATCH algorithm, PWM score thresholds were optimized
to yield a maximal odds ratio. Given counts of predicted binding
sites as well as counts of promoters, we assumed independent Beta
distributions (4) for the foreground proportions.
Beta(x;a,b)~
xa{1:(1{x)
b{1
B(a,b)
;
a,bw0;0vxv1;B(a,b)~
C(a):C(b)
C(azb)
ð4Þ
Regularizing observations with a uniform prior, Beta(a=1,b=1),
promoters were assumed to come from the distribution Beta-
p(ap=p f+1,bp=p b+1), where pf and pb denote the number of
promoters in foreground and background, respectively. Likewise,
the site distribution (at a certain PWM score threshold) was set to
Betas(as=n f+1,bs=n b+1), with nf and nb denoting counts of
predicted binding sites in foreground and background. These
two Beta distributions were used to assess the uncertainty about
true proportions of sites as well as promoters.
For two independent distributions the probability P(w=xs/xp),
with xp , Betap and xs , Betas, can be computed from the joint
density. An exact expression for P(w=x/y) was derived by Pham-
Gia [49] and is recapitulated in (5).
P(w)~
B(axzay,by)
B(ax,bx):B(ay,by)
:wax{1:
2F1(axzay,1{bx;axzayzby;w),0vwƒ1
B(axzay,bx)
B(ax,bx):B(ay,by)
:w{(1zay):
2F1(axzay,1{by;axzayzbx;w),w§1
8
> > > <
> > > :
ð5Þ
To avoid numerical difficulties with evaluating the Gauss
hypergeometric function 2F1 near w=1, we calculated P(w) by
numerical integration of equation (6).
P(w)~
ð t
0
(w:y)
ax{1:(1{wy)
bx{1:yay:(1{y)
by{1dy
B(ax,bx):B(ay,by)
ð6Þ
where
t~
1,wƒ1
w{1,w§1
 
Equation 6 can be evaluated in log-space before exponentiation,
which can be beneficial for large a’s and b’s. Eventually, we used
equation (6) to compute quantile (F
21) estimates of the ratio of
site and promoter proportions by numerical integration. The
p-quantile yields the value for which the cumulative probability is
at most p. In this work, we chose p=0.01, so that the ratio of
corresponding Beta distributions was assumed to be at least as high
with 99% probability. The computer program sought a PWM
score threshold to maximize this quantile value. Hence, a value
F
21(0.01)=2 for a certain PWM means that the proportion of
foreground sites among all predicted sites (foreground +
background) was at least two times higher than the proportion
of foreground promoters among all promoters with 99%
probability which indicates enrichment of sites in foreground
promoters.
Calculation of P-values for MATCH scores
PWM score thresholds for initial MATCH searches were
adjusted to a common background frequency as baseline. Single
binding site analyses used initial theoretically calculated cut-offs
corresponding to a P-value of 0.05. P-values for PWM scores were
computed with the standard method [50], which was extended to
consider searches over both sequence orientations and to adopt a
dinucleotide model for random sequences as described in the
following.
Let Q=( q ik) be the Wx4score matrix with i = 1. .W vectors, in
following called site positions, each with k = 1. .4 scores for residues
R=( r k) = (A,C,G,T). This matrix is used to score an alignment of
the TFBS profile with a sequence segment of length W. The score
function is additive, so that the score S of a sequence segment is
evaluatedbysummingupresiduescoresofallsite positions.Further,
let p =( pk) be a mononucleotide background model. Usually, one
considers both orientations of the sequence or equivalently both
PWM orientations. A method for P-value calculation should take
this into account and determine the probability that either score
(5)
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reverse PWM Q’ is defined in (7) and (8).
Q’~(q’ ik);i~1::W;k~1::4 ð7Þ
q’ ik~q(wz1{i)(5{k) ð8Þ
Given forward and reverse orientations, there is a pair of scores
(qik,q’ik) for each position of an alignment and subsequently a pair of
scores (s,s’) for the sequence segment. As previously shown, the
probability distribution of PWM scores can be efficiently calculated
by convolution [50]. The latter can be extended to calculate the
joint probability density f(s,s’) by the convolution defined in (9).
Equation 9 gives the joint probability density of scores si and s’i upto
site positionibyconvolutionofg(qik,q’ik)andh(si-qik,s’i-q’ik),wheregis
the function of score pairs at site position i of Q and Q’ and h is the
joint probability density of score pairs up to position i-1.
f(si,s’ i)~ g   h ½  (si,s’ i)~
X
k~1::4
g(qik,q’ ik)   h(si{qik,s’ i{q’ ik) ð9Þ
When a mononucleotide background model is used to calculate the
false positive rates of PWM scores, g(qik,q’ik) is just the mapping g:
qik,q’ik R pk. The cumulative probability P(S§t)|P(Sn§t) that
determines selection of score threshold t is derived from the joint
probability density of scores.
We further extendedthe standard method to apply a dinucleotide
background model. By conditioning score functions on the terminal
residue j associated with a score pair (si,s’i), the convolution also
accommodates higher-order background models (10).
fj(si,s’ i)~ gj   hk
  
(si,s’ i)
~
X
k~1::4
g(qij,q’ ij)   hk(si{qij,s’ i{q’ ij);j~1::4 ð10Þ
In this study, we employed a dinucleotide model that was estimated
from the first 1000 residues upstream of all murine TSSs in
TRANSPro. We selected this particular region for several reasons.
First, start positions of 74.4% of the genomic TFBS entries in
TRANSFAC 12.1 map to this sequence range. The distribution of
TSS-relative locations of known binding sites is shown in Figure 1.
While it is well known that transcription factors can exert an effect
on promoters that are located thousands of base pairs away,
TRANSFAC data suggest that functional binding sites are
predominantly located in the proximal upstream region of the
TSS.The distributionshown in Figure 1 has a peak at position –115
(red line). Also, locations of binding sites identified by ChIP-chip or
ChIP-seq are often overrepresented in the TSS vicinity (data not
shown). Second, we did not include downstream residues to avoid
inclusion of coding regions.
Co-occupancy of TF binding sites
An analysis of individual TFBS with a test for pair wise co-
occurrences of binding sites was performed. The approach
represents a variant of the F-MATCH algorithm for binding site
pairs and quantifies overrepresentation of promoter sequences
with sites of both PWMs in the foreground set using the Fisher test.
Like F-MATCH, the site co-occurrence method starts with
externally defined score thresholds that can be further optimized
using minimization of the Fisher test P-value as objective. While
sequences containing a certain binding site pair can be
significantly overrepresented in the foreground set, the association
of the two sites might not be significant per se, e.g. enrichment
may be determined by only one type of sites. Therefore, the signal
conveyed by the event of co-occurrence itself was controlled using
a stringent site score cut-off (P-value 10
-4). Furthermore, the
frequency of sequences with both site types was compared with the
expected frequency in the foreground, given the numbers of
promoters with either TFBS, and calculated a coefficient of
independence (11), which is similar to the mutual information of
two random variables.
CI i,k ðÞ ~
fi ,k ðÞ
f’ i ðÞ :fk ðÞ
ð11Þ
In (11), f(i,k), f(i) and f(k) denote proportions of promoters with the
TFBS pair, site i, and site k, respectively. To further consider a pair,
it was required for this value to be at least 1.3. Finally, dependence
of PWMs with similar sequence specificity was eliminated, because
this property would inevitably produce high co-occurrence rates.
This problem was addressed by considering only pairs of PWMs
showing overlap in less than 10% of predicted sites. This approach
was fully data-driven since admissible PWM combinations, baseline
thresholds, and final score cut-offs, for individual PWMs and for the
pair, were estimated on the basis of a background promoter set that
was defined by the gene expression data.
Supporting Information
Table S1 Differentially expressed genes detected by Ebarrays in
transgenic and tumor cells.
(XLS)
Table S2 Biological processes selected by comparison of their
enrichment P-values in transgenic and tumor state.
(XLS)
Table S3 Upregulated molecules connected in network clusters
shown in Figures 4 and 5.
(XLS)
Table S4 TRANSFAC weight matrices with highest q-values in
transgenic and tumor gene sets.
(XLS)
Table S5 Transcription factors represented by enriched
TRANSFAC motifs.
(XLS)
Table S6 TRANSFAC PWM pairs enriched in upregulated
tumor genes (P , 0.001).
(XLS)
Table S7 Transcription factors identified by PWM co-occur-
rence analysis.
(XLS)
Table S8 Experimental validation of predicted binding sites in
promoters of up- and downregulated genes.
(XLS)
Figure S1 Multiple alignment of TRANSPro promoters (-1000
to +500) of murine Bcl2a1a-d.
(TIF)
Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 24 March 2011 | Volume 6 | Issue 3 | e17738Figure S2 Representation of EGF/IGF-2 regulatory circuit in
SBGN notation. This diagram was constructed using the
geneXplain platform for systems biology (www.genexplain.com)
and adapted with the Inkscape SVG editor (inkscape.org). The
SBGN diagram illustrates the feedback loops triggered by EGF
and IGF-2 signaling. The endpoints of regulation – multiple
transcription factors (shown in light blue) that are activated
through upstream signaling events, regulate expression of their
target genes (shown in light blue) whose products are the key
components of the signaling network (shown in red) upstream of
the transcription factors.
(PNG)
Author Contributions
Conceived and designed the experiments: JB. Performed the experiments:
TM JB. Analyzed the data: PS TM AK EW JB. Contributed reagents/
materials/analysis tools: JB. Wrote the paper: PS AK JB.
References
1. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K (2005) Epidermal
growth factor-induced hepatocellular carcinoma: gene expression profiles in
precursor lesions, early stage and solitary tumours. Oncogene 24: 1809–1819.
2. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a novel method for
rapid multiple sequence alignment based on fast Fourier transform. Nucleic
Acids Res 30: 3059–3066.
3. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ (2009) Jalview
Version 2 - a multiple sequence alignment editor and analysis workbench.
Bioinformatics 25: 1189–1191.
4. Michael H, Hogan J, Kel AE, Kel-Margoulis O, Schacherer F, et al. (2008)
Building a knowledge base for systems pathology. Brief. Bioinformatics 9:
518–531.
5. Nioi P, Pardo ID, Sherratt PJ, Snyder RD (2008) Prediction of non-genotoxic
carcinogenesis in rats using changes in gene expression following acute dosing.
Chem Biol Interact 176: 252–260.
6. Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and
lipoprotein metabolism. Lipids Health Dis 5: 4.
7. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple
myeloma. Leukemia 23: 1964–1979.
8. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, et al. (2008)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinat-
ing activity and nuclear localization. Cancer Res 68: 6953–6962.
9. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, et al. (2003) Integrin
alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell
invasion across the fibrotic matrix microenvironment. Cancer Res 63:
8312–8317.
10. Hayashida K, Shimaoka Y, Ochi T, Lipsky PE (2000) Rheumatoid arthritis
synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B
cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 164:
1110–1116.
11. Yeh LC, Lee JC (2000) Identification of an osteogenic protein-1 (bone
morphogenetic protein-7)-responsive element in the promoter of the rat
insulin-like growth factor-binding protein-5 gene. Endocrinology 141:
3278–3286.
12. Shea CM, Edgar CM, Einhorn TA, Gerstenfeld LC (2003) BMP treatment of
C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and
osteogenesis. J Cell Biochem 90: 1112–1127.
13. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, et al. (2003) Bone
morphogenetic proteins induce apoptosis in human pulmonary vascular smooth
muscle cells. Am J Physiol Lung Cell Mol Physiol 285: L740–54.
14. Figueroa JA, Lee AV, Jackson JG, Yee D (1995) Proliferation of cultured human
prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding
protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol
Metab 80: 3476–3482.
15. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, et al. (2005) Oct4
expression in adult human stem cells: evidence in support of the stem cell theory
of carcinogenesis. Carcinogenesis 26: 495–502.
16. Guo Y, Costa R, Ramsey H, Starnes T, Vance G, et al. (2002) The embryonic
stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-
specific promoter expression. Proc Natl Acad Sci U S A 99: 3663–3667.
17. Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, et al. (2008) Kaiso
contributes to DNA methylation-dependent silencing of tumor suppressor genes
in colon cancer cell lines. Cancer Res 68: 7258–7263.
18. van Roy FM, McCrea PD (2005) A role for Kaiso-p120ctn complexes in cancer?
Nat Rev Cancer 5: 956–964.
19. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, et al. (2007) Analysis of
Oct4-dependent transcriptional networks regulating self-renewal and pluripo-
tency in human embryonic stem cells. Stem Cells 25: 500–510.
20. Otaegi G, Yusta-Boyo MJ, Vergan ˜o-Vera E, Me ´ndez-Go ´mez HR, Carrera AC,
et al. (2006) Modulation of the PI 3-kinase-Akt signalling pathway by IGF-I and
PTEN regulates the differentiation of neural stem/precursor cells. J Cell Sci 119:
2739–2748.
21. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, et al. (2004) Insulin-like
growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839;
Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:
793–814.
22. Morin S, Charron F, Robitaille L, Nemer M (2000) GATA-dependent
recruitment of MEF2 proteins to target promoters. EMBO J 19: 2046–2055.
23. Mietus-Snyder M, Sladek FM, Ginsburg GS, Kuo CF, Ladias JA, et al. (1992)
Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF,
and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression
in liver and intestinal cells. Mol Cell Biol 12: 1708–1718.
24. Galson DL, Tsuchiya T, Tendler DS, Huang LE, Ren Y, et al. (1995) The
orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator
for tissue-specific and hypoxia-specific erythropoietin gene expression and is
antagonized by EAR3/COUP-TF1. Mol Cell Biol 15: 2135–2144.
25. ENCODE Project Consortium. (2007) Identification and analysis of functional
elements in 1% of the human genome by the ENCODE pilot project. Nature
447: 799–816.
26. Sala A (2005) B-MYB, a transcription factor implicated in regulating cell cycle,
apoptosis and cancer. Eur J Cancer 41: 2479–2484.
27. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoe ¨l MJ, Barbu V,
Fartoux L, et al. (2006) Impact of IGF-1R/EGFR cross-talks on hepatoma
cell sensitivity to gefitinib. Int J Cancer 119: 2557–2566.
28. Riedemann J, Sohail M, Macaulay VM (2007) Dual silencing of the EGF and
type 1 IGF receptors suggests dominance of IGF signaling in human breast
cancer cells. Biochem Biophys Res Commun 355: 700–706.
29. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, et al. (2009) Loss of STAT5
causes liver fibrosis and cancer development through increased TGF-{beta} and
STAT3 activation. J Exp Med 206: 819–831.
30. Fu Y, Luo L, Luo N, Zhu X, Garvey WT (2007) NR4A orphan nuclear
receptors modulate insulin action and the glucose transport system: potential role
in insulin resistance. J Biol Chem 282: 31525–31533.
31. Seth A, Watson DK (2005) ETS transcription factors and their emerging roles in
human cancer. Eur J Cancer 41: 2462–2478.
32. DeChiara TM, Robertson EJ, Efstratiadis A (1991) Parental imprinting of the
mouse insulin-like growth factor II gene. Cell 64: 849–59.
33. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of
human cancer. Nature Reviews 7: 21–33.
34. Fu VX, Schwarze SR, Kenowski ML, Leblanc S, Svaren J, et al. (2004) A loss of
insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor
down-regulation at senescence in human epithelial cells. J Biol Chem 279:
52218–26.
35. Kendziorski CM, Newton MA, Lan H, Gould MN (2003) On parametric
empirical Bayes methods for comparing multiple groups using replicated gene
expression profiles. Stat Med 22: 3899–3914.
36. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
37. Kel A, Voss N, Valeev T, Stegmaier P, Kel-Margoulis O, et al. (2008) ExPlain:
finding upstream drug targets in disease gene regulatory networks. SAR QSAR
Environ Res 19: 481–494.
38. Wingender E, Crass T, Hogan JD, Kel AE, Kel-Margoulis OV, et al. (2007)
Integrative content-driven concepts for bioinformatics ‘‘beyond the cell’’. J Biosci
32: 169–180.
39. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, et al. (2006)
TRANSFAC and its module TRANSCompel: transcriptional gene regulation in
eukaryotes. Nucleic Acids Res 34(Database issue): D108–110.
40. Kel A, Voss N, Jauregui R, Kel-Margoulis O, Wingender E (2006) Beyond
microarrays: find key transcription factors controlling signal transduction
pathways. BMC Bioinformatics 7(Suppl 2): S13.
41. Schmid CD, Perier R, Praz V, Bucher P (2006) EPD in its twentieth year:
towards complete promoter coverage of selected model organisms. Nucleic Acids
Res 34(Database issue): D82–85.
42. Yamashita R, Wakaguri H, Sugano S, Suzuki Y, Nakai K (2010) DBTSS
provides a tissue specific dynamic view of Transcription Start Sites. Nucleic
Acids Res 38(Database issue): D98–104.
43. Hubbard TJP, Aken BL, Ayling S, Ballester B, Beal K, et al. (2009) Ensembl
2009. Nucleic Acids Res 37(Database issue): D690–697.
44. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, et al. (2006)
Genome-wide analysis of mammalian promoter architecture and evolution. Nat
Genet 38: 626–635.
45. Krull M, Pistor S, Voss N, Kel A, Reuter I, et al. (2006) TRANSPATH: an
information resource for storing and visualizing signaling pathways and their
pathological aberrations. Nucleic Acids Res 34(Database issue): D546–551.
Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 25 March 2011 | Volume 6 | Issue 3 | e1773846. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene
ontology: tool for the unification of biology. The Gene Ontology Consortium.
Nat Genet 25: 25–29.
47. Kel AE, Kel-Margoulis OV, Farnham PJ, Bartley SM, Wingender E, et al.
(2001) Computer-assisted identification of cell cycle-related genes: new targets
for E2F transcription factors. J Mol Biol 309: 99–120.
48. Kel AE, Goessling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, et al.
(2003) MATCH
TM: a tool for searching transcription factor binding sites in
DNA sequences. Nucleic Acids Res 31: 3576–3579.
49. Pham-Gia T (2000) Distributions of the ratios of independent beta variables and
applications. In Communications in Statistics - Theory and Methods
Smith BWilliam, ed. London: Taylor & Francis 29(12): 2693–2715.
50. Rahmann S, Mu ¨ller T, Vingron M (2003) On the power of profiles for
transcription factor binding site detection. Stat Appl Genet Mol Biol. pp
Article7.
Oncogenic Signalling of EGFR in Liver Cancer
PLoS ONE | www.plosone.org 26 March 2011 | Volume 6 | Issue 3 | e17738